Stock-Exchange Listing and Delisting
Table of Contents
Stock-exchange listing and delisting affect how easily investors can buy or sell shares and what information they can expect from the issuer. A company can receive a deficiency notice and still trade while it works toward compliance. In another case, trading can stop before formal delisting takes effect. Identifying the actual event matters more than reacting to a headline.
This guide covers ordinary U.S. company shares on Nasdaq and the New York Stock Exchange, with rules checked as of November 14, 2026. Requirements vary by exchange, market tier, security and listing route. NYSE American, funds, SPACs and foreign issuers have additional or different rules.
What Does Stock-Exchange Listing Mean?
A listing admits a class of securities to an exchange under its rules. The issuer must satisfy entry requirements and maintain the applicable financial, shareholder-distribution, disclosure and corporate-governance standards. Meeting numerical thresholds alone does not necessarily secure approval; exchanges also assess suitability. [1] [3]
Initial listing is the entry test. Continued listing is the ongoing test. Delisting removes the security from that exchange. None of these labels, by itself, tells you the company’s fair value or guarantees a willing buyer.
Listing differs from raising money. An initial public offering sells shares to investors; exchange admission establishes a venue and rule framework for subsequent trading. Other listing routes also exist, and a transfer between exchanges need not involve a new public offering.
Initial vs Continued-Listing Requirements
Exchanges consider share price, the number and value of public shares, shareholder distribution, financial strength and governance together. Publicly held shares are not the same as all shares outstanding. Specified insider or concentrated holdings can be excluded, and definitions differ across rules. A large market capitalization therefore does not automatically satisfy a public-float requirement.
These selected requirements illustrate entry and maintenance for ordinary operating-company equity. They are not complete eligibility checklists. [1] [3]
| Requirement | Nasdaq Capital Market | NYSE |
|---|---|---|
| Initial share price | $4 minimum bid price under Rule 5505(a)(1). | $4 share price in the ordinary IPO distribution standards. |
| Selected initial distribution tests | 1 million unrestricted publicly held shares and 300 round-lot holders; at least half those holders must each hold unrestricted securities worth at least $2,500. | For an ordinary IPO: 1.1 million publicly held shares, $40 million public-share market value and 400 North American round-lot holders, subject to specified exceptions. |
| Financial and qualitative tests | One applicable financial standard, alongside other listing, disclosure and governance obligations. | An applicable financial standard, governance requirements and suitability review, alongside distribution requirements. |
| Continued share-price test | At least $1 bid price; the ordinary deficiency and cure process is explained below. | A 30-trading-day average closing price below $1 triggers the ordinary price-deficiency framework. |
Continued financial and distribution requirements remain relevant. Nasdaq Capital Market Rule 5550 includes shareholder, public-share, public-share-value and market-maker tests, plus an applicable financial standard. A price recovery does not cure a separate equity or reporting problem. Conversely, a company can breach a financial standard while its price remains above $1.
Use the current rule for the actual exchange and security. An older guide may show Nasdaq’s former $2 or $3 alternative initial-price route; the current rulebook says that route no longer applies to new listings. [1]
What a Deficiency Notice Actually Means
A deficiency notice identifies a breached rule and the applicable next steps. Depending on the breach, the issuer may receive time to cure, submit a compliance plan, or face a delisting determination. A notice allowing a cure period differs from an instruction that trading will be suspended.
For a U.S. registrant subject to Form 8-K, Item 3.01 generally requires disclosure of a covered listing notice within four business days, including the rule involved and the response determined at the time. A grace period does not eliminate that obligation. Nasdaq also has its own public-announcement requirement. Not every issuer uses Form 8-K, and the form contains specific exceptions. [2] [6]
Start with the issuer’s filed disclosure. Record the breached rule, notice date, cure deadline, proposed action, other deficiencies and any stated suspension date. Read later filings to find whether the exchange actually confirmed compliance. Our guide to reading 10-K and 10-Q reports helps place the event alongside the company’s financial position.
RAPT Therapeutics, May 2025: its Form 8-K reported a Nasdaq minimum-bid-price notice and an initial 180-calendar-day compliance period. The filing said the notice had no immediate listing impact, subject to other requirements, and discussed a proposed reverse split. This was a price-deficiency notice, not evidence that a split had already cured it. [7]
Skillsoft, March 2026: its Form 8-K reported a NYSE notice involving both a 30-trading-day average market capitalization below $50 million and latest reported equity below $50 million. It described a business-plan process and an 18-month cure period subject to NYSE approval and continuing review. That financial-deficiency process differs from the ordinary six-month price cure. [8]
These are dated examples of the notices reported then, not statements about either company’s current status or eventual outcome.
Nasdaq vs NYSE: Price Deficiency and Cure
Both exchanges use a $1 benchmark in their ordinary continued-price framework, but they measure a breach and recovery differently. Nasdaq’s closing bid differs from the NYSE’s average closing transaction price. Keep business days, trading days and calendar days distinct. [2] [4]
| Question | Nasdaq | NYSE |
|---|---|---|
| Ordinary deficiency trigger | Minimum-bid-price deficiency continues for 30 consecutive business days. | Average closing price below $1 over 30 consecutive trading days. |
| Ordinary initial cure period | 180 calendar days from notification. | Six months from notification; notify the exchange of intent to cure within 10 business days. |
| Ordinary recovery test | Closing bid of at least $1 for at least 10 consecutive business days. Staff can require longer, generally no more than 20 consecutive business days. | At a calendar month-end during the cure period, both the closing price and trailing 30-trading-day average closing price must be at least $1. Both measures also matter at the end of the cure period. |
| Additional time | A second 180-day Capital Market period has conditions, including other listing qualifications and the intent and ability to cure. A qualifying transfer from another Nasdaq tier may be relevant. | The ordinary price process is separate from compliance-plan procedures for other deficiencies. Shareholder-approved corrective action has a specific alternative procedure. |
For the NYSE shareholder-approval route, the company must inform the exchange that its proposed cure requires shareholder approval, obtain approval by its next annual meeting and implement the action promptly afterward. Recovery under that route requires the price promptly to exceed $1 and remain above it for at least the following 30 trading days. It is not an unrestricted extension of every six-month deadline. [4]
Exceptions can accelerate action. On Nasdaq, a closing bid at or below $0.10 for ten consecutive business days triggers a staff delisting determination and suspension without the ordinary compliance period. Prior reverse splits can also remove eligibility for that period. For the NYSE, the SEC’s 2026 order describes existing prompt action when a stock trades below $0.10, regardless of its position in a cure period. [2] [5]
The SEC approved a NYSE rule requiring immediate suspension and delisting proceedings when a security closes below $0.25 on any trading day, but its effective date is July 1, 2027. It is not the operative $0.25 trigger as of November 14, 2026. An approval announcement and an effective rule can have different dates. [5]
A hearing request does not guarantee continued trading
Nasdaq generally allows seven calendar days to request a hearing after a staff delisting determination. A timely request ordinarily stays suspension and delisting, with exceptions. For example, a failed second 180-day bid-price period or the $0.10 trigger does not receive the ordinary suspension stay. Other cases, including filing delinquencies and bankruptcy, have their own treatment. Further appeals are separate. [2]
NYSE issuers also retain appeal rights. Those rights do not establish the Nasdaq deadline or stay rules for a NYSE case. Read the actual determination and exchange procedure to identify what is suspended, what can be challenged and whether trading can continue. A planned appeal is not a confirmed cure. [5]
Can a Reverse Stock Split Prevent Delisting?
A reverse split consolidates existing shares into fewer shares. It can raise the quoted price mechanically and help address a minimum-price deficiency. It does not, by itself, add cash, reduce debt or repair operating losses. Actual trading prices can move afterward, and some fractional holdings may be paid in cash. Approval requirements depend on applicable corporate law and company documents. [9]
Consider Meridian, a fictional company, with 20 million shares outstanding at $0.40. An investor owns 2,000 shares. Assume a 1-for-10 reverse split, proportional price adjustment, no fees, no fractional shares, no new issuance and no other change in value.
| Measure | Before | Mechanical result |
|---|---|---|
| Investor’s shares | 2,000 | 2,000 / 10 = 200 |
| Price per share | $0.40 | $0.40 × 10 = $4.00 |
| Investor’s holding value | 2,000 × $0.40 = $800 | 200 × $4.00 = $800 |
| Company shares outstanding | 20 million | 20 million / 10 = 2 million |
| Company market capitalization | 20 million × $0.40 = $8 million | 2 million × $4.00 = $8 million |
The investor still owns 0.01%: 2,000 / 20 million before, and 200 / 2 million afterward. If shares subsequently trade at $3, the holding becomes 200 × $3 = $600, a ($600 − $800) / $800 = −25% change. The split provided no return or price guarantee. The same share-count distinction appears in dividend policy and stock splits.
Why exchange rules limit repeated reverse-split cures
When a company is below the applicable minimum-price standard, recent split history can remove the ordinary cure period:
- Nasdaq: a reverse split during the preceding year, or one or more splits with a cumulative ratio of at least 250-for-1 over the preceding two years.
- NYSE: a reverse split during the preceding year, or one or more splits with a cumulative ratio of at least 200-for-1 over the preceding two years. [2] [4]
Cumulative ratios multiply: a 1-for-10 split followed by a 1-for-25 split consolidates 10 × 25 = 250 original shares into one, not 35. These history tests apply alongside the current price deficiency; the historical split alone is not the whole trigger.
A split can also create another problem by reducing public-share or holder counts. Nasdaq does not recognize a price cure from an action that creates another numerical deficiency until the other deficiency is cured and the price test is then satisfied within the applicable period. NYSE rules prohibit a reverse split that would put the security below its Section 802.01A distribution requirements. Raising the price while breaking a different standard does not solve the listing problem. [2] [4]
Voluntary vs Involuntary Delisting
Involuntary delisting follows an exchange decision, such as a failure to maintain standards. Voluntary delisting begins with the issuer’s decision to withdraw, subject to applicable law and exchange procedures. It may accompany a transfer to another exchange, a merger or a decision to leave exchange trading. Voluntary withdrawal does not erase an existing compliance problem. [2]
The shareholder’s economic outcome depends on the accompanying transaction. A merger or tender offer may provide cash or replacement securities under its terms. A bare exchange withdrawal does not itself promise a buyout at the last traded price. Read the transaction documents, including any applicable going-private disclosures, to identify consideration, elections and deadlines. [14]
Form 25 vs Ending SEC Reporting
Trading suspension, formal exchange removal and SEC registration withdrawal use different clocks. Form 25 addresses removal from listing and/or registration under Exchange Act Section 12(b). It is not a blanket cancellation of every SEC reporting obligation. [10]
| Event | What changes? | Timing to check |
|---|---|---|
| Trading suspension | Trading on the exchange stops. | Can occur before formal delisting; use the exchange’s stated suspension date. |
| Form 25 filing | Starts the filing-based removal process. | Find the actual filing date and any amendment. |
| Removal from listing | The class is formally delisted from the exchange. | Normally effective 10 days after Form 25 is filed. |
| Withdrawal of Section 12(b) registration | Ends that exchange-registration basis. | Normally 90 days after filing, or a shorter SEC-determined period; SEC action can delay effectiveness. |
At effective delisting, the duty to file reports arising solely from Section 12(b) registration is suspended. However, registration or reporting requirements under Section 12(g) or Section 15(d) can remain. A company may therefore continue filing SEC reports while trading OTC. [10]
Form 15, where the issuer qualifies, is a separate step used for specified registration-termination or reporting-suspension purposes. SEC staff guidance says Form 15 for the securities being delisted cannot be filed before effective delisting under Form 25. Do not infer “no more public reports” from a Form 25 headline; check the legal basis, eligibility and subsequent filings. [11]
What Happens to Shares After Delisting?
Exchange removal alone does not automatically cancel your shares or turn them into cash. Shares may continue trading over the counter, remain listed on another exchange, or become difficult to trade. Cancellation, cash payment or replacement shares depend on separate corporate or bankruptcy events.
OTC trading is possible, not guaranteed. A quote, a willing counterparty and your broker’s support all matter. FINRA explains that some OTC equities have limited liquidity, greater volatility or less publicly available information; some issuers continue SEC reporting and others do not. Also, an exchange-listed stock can trade off-exchange, so “traded OTC” alone does not establish that it was delisted. [12]
A displayed last price is a past trade, not a guaranteed sale price for your position. Thin trading can leave no buyer at the price or size you need. The practical risk is losing an accessible exit while the business risk continues.
How to Evaluate Your Exit Options
Decide using both the issuer’s prospects and the available trading route. A cure announcement does not replace fundamental analysis, and an exchange deadline does not establish the right investment decision for every shareholder.
- Identify the exact event. Separate a deficiency notice, delisting determination, suspension, filed Form 25 and completed transaction. Verify dates from filings and exchange notices.
- Assess the proposed cure. Determine which rule it addresses, whether approval or financing is required, and whether other deficiencies remain.
- Ask your broker about access before trading changes. Confirm whether it supports sales, purchases, holding or transfer of the specific security; ask about order types, fees, margin treatment and corporate-action handling. Do not assume another firm will accept a transfer.
- Compare selling with continuing to hold. Selling requires an executable market and may realize a loss. Holding retains economic risk and may leave less liquidity or information. A transfer changes custody, not the issuer’s condition.
- Read any offer separately. A tender offer, merger payment or fractional-share cashout has its own terms. Confirm eligibility, deadlines and how your broker will process it.
- Control execution risk where possible. If available, a sell limit order sets a minimum execution price, but it may never fill. A market order does not guarantee the price. Recheck live quotes and available size rather than relying on the old exchange close. [13]
The broader trading execution guide explains how order choice and market conditions affect fills. No order type can create a buyer or guarantee an exit after trading becomes restricted.
Common Mistakes
- Treating a notice as immediate delisting. Some notices allow cure, while others lead to prompt suspension.
- Assuming every issuer receives 360 days. Nasdaq’s additional period is conditional, and other deficiencies and exchanges use different processes.
- Counting one day above $1 as a cure. The sustained-price or average-price test still has to be met.
- Using the same rule for Nasdaq and NYSE. Price measures, cure tests and reverse-split thresholds differ.
- Calling a reverse split a recovery in value. Fewer shares at a proportionately higher price do not themselves improve the business.
- Assuming Form 25 ends all reporting or guarantees OTC trading. Reporting status and market access require separate checks.
Limitations and Risks Beyond the Listing Rules
A listing decision is not a complete credit, valuation or fraud assessment. An issuer may satisfy exchange standards while facing substantial business risk. Regaining price compliance does not establish sustainable cash flow, and an available appeal does not ensure success.
If the company is bankrupt, common shareholders stand behind creditors, and a reorganization can cancel the old shares even if the business survives. Continued trading does not establish that old equity will receive value. Read the actual plan rather than assuming that a surviving company means surviving shares. [15]
This guide does not determine legal remedies, tax deductibility or whether shares are worthless for tax purposes. Delisting alone does not answer those questions. Exchange rules and broker policies can change; use current rules and security-specific notices for an actual case.
Frequently Asked Questions
Sources
- Nasdaq: Rule 5500 Series, especially 5501, 5505, IM-5505-2 and 5550. Current Capital Market requirements.
- Nasdaq: Rule 5800 Series, especially 5810, 5815, 5820 and 5840(j). Deficiencies, cures, hearings, disclosure and withdrawal.
- NYSE: Initial Listing Standards Summary, January 2026. Initial financial and distribution standards.
- SEC: Release 34-102201, January 15, 2025. NYSE price cures and approved reverse-split restrictions.
- SEC: Release 34-106133, August 14, 2026. NYSE price framework and the July 1, 2027 effective date for the $0.25 rule.
- SEC: Form 8-K, General Instruction B and Item 3.01. Listing notices and disclosure timing.
- RAPT Therapeutics: Form 8-K signed May 28, 2025, Item 3.01. Historical price-deficiency example.
- Skillsoft: Form 8-K filed March 27, 2026, Item 3.01. Historical financial-deficiency example.
- SEC Investor.gov: Reverse Stock Splits. Mechanics, fractional cashouts and approval considerations.
- SEC: Form 25 and General Instructions. Exchange removal, registration withdrawal and remaining reporting duties.
- SEC: Exchange Act Forms, Question 111.01. Form 15 cannot precede effective delisting under Form 25.
- FINRA: A Look at Over-the-Counter Equities Trading, April 25, 2024. Market structure, liquidity and information risks.
- FINRA: Understanding Order Types Can Save Time and Money. Limit prices, execution uncertainty and firm-specific availability.
- SEC Investor.gov: Going Private. Transactions and separate disclosures.
- SEC Investor.gov: Bankruptcy for a Public Company. Creditor priority and old-common-stock cancellation risk.
Sources accessed November 14, 2026. Exchange examples are selective, dated illustrations. Meridian and its calculations are hypothetical.
Disclaimer
This article is for educational and informational purposes only and does not constitute investment, legal or tax advice. Rules, issuer circumstances and broker policies can change. Confirm current exchange requirements, company filings and account-specific trading arrangements, and consult qualified professionals about your circumstances.
